Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about OKYO Pharma Limited
OKYO Pharma Limited News
OKYO Pharma Limited Quantitative Score
About OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Pharma Limited Earnings & Revenue
OKYO Pharma Limited Financials
Table Compare
Compare OKYO metrics with: | |||
|---|---|---|---|
Earnings & Growth | OKYO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | OKYO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | OKYO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | OKYO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
OKYO Pharma Limited Income
OKYO Pharma Limited Balance Sheet
OKYO Pharma Limited Cash Flow
OKYO Pharma Limited Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
OKYO Pharma Limited Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
OKYO Pharma Limited Executives
| Name | Role |
|---|---|
| Dr. Gary S. Jacob Ph.D. | Chief Executive Officer & Executive Director |
| Ms. Keeren Shah | Chief Financial Officer |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer |
| Mr. Michael Paul Beck | Founder |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Gary S. Jacob Ph.D. | Chief Executive Officer & Executive Director | 1947 | 588K | |
| Ms. Keeren Shah | Chief Financial Officer | Female | 1975 | -- |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer | 1959 | -- | |
| Mr. Michael Paul Beck | Founder | Male | 1957 | -- |
OKYO Pharma Limited Insider Trades
| Date | 23 Oct |
| Name | CERRONE GABRIELE M |
| Role | Executive Chairman |
| Transaction | Acquired |
| Type | J-Other |
| Shares | 499468 |
| Date | 27 Oct |
| Name | CERRONE GABRIELE M |
| Role | Executive Chairman |
| Transaction | Acquired |
| Type | J-Other |
| Shares | 70071 |
| Date | 15 Sep |
| Name | BRANCACCIO JOHN P |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 16670 |
| Date | 19 May |
| Name | CERRONE GABRIELE M |
| Role | Executive Chairman |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 5800000 |
| Date | 19 May |
| Name | JACOB GARY S |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 12500 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 23 Oct | CERRONE GABRIELE M | Executive Chairman | Acquired | J-Other | 499468 |
| 27 Oct | CERRONE GABRIELE M | Executive Chairman | Acquired | J-Other | 70071 |
| 15 Sep | BRANCACCIO JOHN P | Director | Acquired | P-Purchase | 16670 |
| 19 May | CERRONE GABRIELE M | Executive Chairman | Acquired | P-Purchase | 5800000 |
| 19 May | JACOB GARY S | Chief Executive Officer | Acquired | P-Purchase | 12500 |